Nanosep is a company with a new high performing environmentally friendly analytical technology to be used in the pharmaceutical and biotech industry. With the Nanosep technology, a customer can easily get results from complicated samples, such as blood plasma and pharmaceutical products. Both faster, with less effort and with higher precision compared to technologies available on the market today
Missing: Nanosep's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Nanosep's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Nanosep Frequently Asked Questions (FAQ)
When was Nanosep founded?
Nanosep was founded in 2003.
What is Nanosep's latest funding round?
Nanosep's latest funding round is Other Investors.
Who are the investors of Nanosep?
Investors of Nanosep include MedCap, Lumitec and Lunds Universitets Innovation System.
Who are Nanosep's competitors?
Competitors of Nanosep include Sirion Biotech, Gyros, HTG Molecular Diagnostics, Life Technologies Corporation, Crossject Medical Technology and 12 more.
Compare Nanosep to Competitors
Shamrock Structures is a structural proteomics company focused on assisting pharmaceutical and biotechnology clients reduce the time it takes to advance from protein targets to drugs by offering integrated services in structural proteomics including protein cloning, expression, purification and crystallization.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
microLAN: from chemical analysers to Bioassays:It still is impossible to analyse all chemical substances, which are brought into nature by man. Scientists suggest there are around 100.000 dangerous chemical substances and even with instruments it is still not possible to detect them all. With the help of bioassays a much broader view of the possible dangerous effects can be analysed there where it is most important: nature itself!!With analytical / chemical testing only 5% can be detected, specially in waste and riverwater.Bioassays are more and more commonly used in combination with the traditional chemical analysers for the analyses of soil, water and sediment.
Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.
Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.
VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.